Cargando…

Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability

Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn’s disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment’s effectiveness. Research on predictors for anti-TNF treatment responsiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Cozijnsen, M. A., Samsom, J. N., de Ridder, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775976/
https://www.ncbi.nlm.nih.gov/pubmed/29079905
http://dx.doi.org/10.1007/s40272-017-0266-9
_version_ 1783293998930067456
author Cozijnsen, M. A.
Samsom, J. N.
de Ridder, L.
author_facet Cozijnsen, M. A.
Samsom, J. N.
de Ridder, L.
author_sort Cozijnsen, M. A.
collection PubMed
description Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn’s disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment’s effectiveness. Research on predictors for anti-TNF treatment responsiveness has revealed potential markers, but data on their accuracy in paediatric CD patients are lagging behind. Also, new evidence has become available on the safety profile of anti-TNF antibodies that suggests the assumed increased malignancy risk seen in patients on anti-TNF and thiopurine combination treatment may be linked more to thiopurine use and not to anti-TNF treatment. In addition, the early results of CT-P13, an infliximab biosimilar, in CD patients confirm the expected similarity with its originator. Thus, the effectiveness of anti-TNF antibody treatment is slowly improving, its malignancy risk is lower than assumed, and its costs are reduced by the introduction of equally effective biosimilars. Together, these trends allow for a more prominent role for anti-TNF antibodies in future treatment of paediatric CD.
format Online
Article
Text
id pubmed-5775976
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-57759762018-01-30 Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability Cozijnsen, M. A. Samsom, J. N. de Ridder, L. Paediatr Drugs Leading Article Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn’s disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment’s effectiveness. Research on predictors for anti-TNF treatment responsiveness has revealed potential markers, but data on their accuracy in paediatric CD patients are lagging behind. Also, new evidence has become available on the safety profile of anti-TNF antibodies that suggests the assumed increased malignancy risk seen in patients on anti-TNF and thiopurine combination treatment may be linked more to thiopurine use and not to anti-TNF treatment. In addition, the early results of CT-P13, an infliximab biosimilar, in CD patients confirm the expected similarity with its originator. Thus, the effectiveness of anti-TNF antibody treatment is slowly improving, its malignancy risk is lower than assumed, and its costs are reduced by the introduction of equally effective biosimilars. Together, these trends allow for a more prominent role for anti-TNF antibodies in future treatment of paediatric CD. Springer International Publishing 2017-10-27 2018 /pmc/articles/PMC5775976/ /pubmed/29079905 http://dx.doi.org/10.1007/s40272-017-0266-9 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Leading Article
Cozijnsen, M. A.
Samsom, J. N.
de Ridder, L.
Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
title Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
title_full Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
title_fullStr Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
title_full_unstemmed Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
title_short Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
title_sort anti-tumour necrosis factor therapy for paediatric crohn’s disease: improved benefits through treatment optimisation, deeper understanding of its risks, and reduced costs due to biosimilar availability
topic Leading Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775976/
https://www.ncbi.nlm.nih.gov/pubmed/29079905
http://dx.doi.org/10.1007/s40272-017-0266-9
work_keys_str_mv AT cozijnsenma antitumournecrosisfactortherapyforpaediatriccrohnsdiseaseimprovedbenefitsthroughtreatmentoptimisationdeeperunderstandingofitsrisksandreducedcostsduetobiosimilaravailability
AT samsomjn antitumournecrosisfactortherapyforpaediatriccrohnsdiseaseimprovedbenefitsthroughtreatmentoptimisationdeeperunderstandingofitsrisksandreducedcostsduetobiosimilaravailability
AT deridderl antitumournecrosisfactortherapyforpaediatriccrohnsdiseaseimprovedbenefitsthroughtreatmentoptimisationdeeperunderstandingofitsrisksandreducedcostsduetobiosimilaravailability